Literature DB >> 12559917

Ebola virus matrix protein VP40 interaction with human cellular factors Tsg101 and Nedd4.

Joanna Timmins1, Guy Schoehn, Sylvie Ricard-Blum, Sandra Scianimanico, Thierry Vernet, Rob W H Ruigrok, Winfried Weissenhorn.   

Abstract

The Ebola virus matrix protein VP40 is a major viral structural protein and plays a central role in virus assembly and budding at the plasma membrane of infected cells. For efficient budding, a full amino terminus of VP40 is required, which includes a PPXY and a PT/SAP motif, both of which have been proposed to interact with cellular proteins. Here, we report that Ebola VP40 can interact with cellular factors human Nedd4 and Tsg101 in vitro. We show that WW domain 3 of human Nedd4 is necessary and sufficient for binding to the PPXY motif of VP40, which requires an oligomeric conformation of VP40. Single particle electron microscopy reconstructions indicate that WW3 of Nedd4 is in close contact with the N-terminal domain of hexameric VP40. In contrast, the ubiquitin enzyme variant domain of Tsg101 was sufficient for binding to the PT/SAP motif of VP40, regardless of the oligomeric state of the matrix protein. These results suggest that hNedd4 and Tsg101 may play complimentary roles at a late stage of the assembly process, by recruiting cellular factors of two independent pathways to the site of budding at the plasma membrane.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12559917     DOI: 10.1016/s0022-2836(02)01406-7

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  93 in total

1.  The small RING finger protein Z drives arenavirus budding: implications for antiviral strategies.

Authors:  Mar Perez; Rebecca C Craven; Juan C de la Torre
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-16       Impact factor: 11.205

2.  The matrix protein of Marburg virus is transported to the plasma membrane along cellular membranes: exploiting the retrograde late endosomal pathway.

Authors:  Larissa Kolesnikova; Sandra Bamberg; Beate Berghöfer; Stephan Becker
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

3.  Unconventional secretion of Ebola virus matrix protein VP40.

Authors:  Olivier Reynard; St Patrick Reid; Audrey Page; Mathieu Mateo; Nathalie Alazard-Dany; Hervé Raoul; Christopher F Basler; Viktor E Volchkov
Journal:  J Infect Dis       Date:  2011-11       Impact factor: 5.226

4.  Viral and host proteins that modulate filovirus budding.

Authors:  Yuliang Liu; Ronald N Harty
Journal:  Future Virol       Date:  2010-07-01       Impact factor: 1.831

5.  Oligomerization of Ebola virus VP40 is essential for particle morphogenesis and regulation of viral transcription.

Authors:  T Hoenen; N Biedenkopf; F Zielecki; S Jung; A Groseth; H Feldmann; S Becker
Journal:  J Virol       Date:  2010-05-12       Impact factor: 5.103

Review 6.  Conformational plasticity of the Ebola virus matrix protein.

Authors:  Jens Radzimanowski; Gregory Effantin; Winfried Weissenhorn
Journal:  Protein Sci       Date:  2014-09-04       Impact factor: 6.725

7.  Characterization of the Interaction between the Matrix Protein of Vesicular Stomatitis Virus and the Immunoproteasome Subunit LMP2.

Authors:  Frauke Beilstein; Linda Obiang; Hélène Raux; Yves Gaudin
Journal:  J Virol       Date:  2015-08-26       Impact factor: 5.103

8.  Evidence for a new viral late-domain core sequence, FPIV, necessary for budding of a paramyxovirus.

Authors:  Anthony P Schmitt; George P Leser; Eiji Morita; Wesley I Sundquist; Robert A Lamb
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

9.  Analysis of human immunodeficiency virus type 1 Gag ubiquitination.

Authors:  Eva Gottwein; Hans-Georg Kräusslich
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

10.  Lassa virus Z protein is a matrix protein and sufficient for the release of virus-like particles [corrected].

Authors:  Thomas Strecker; Robert Eichler; Jan ter Meulen; Winfried Weissenhorn; Hans Dieter Klenk; Wolfgang Garten; Oliver Lenz
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.